Contact Information: Contact: The Global Consulting Group Rachel Levine T: (646) 284-9439 E:
Cleveland BioLabs to Present at Noble Financial Conference
| Source: Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwire - August 14, 2007) - Cleveland BioLabs, Inc. (NASDAQ : CBLI ) (BOST : CBLI ), today announced that the Company is scheduled to present at the
Noble Financial Two Double-0-Seven Small Cap Conference and Micro Cap
Symposium, August 20-21, 2007, in Charleston, South Carolina.
Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland
BioLabs, will give a presentation on the Company followed by a question and
answer session on August 20, at 4:30 p.m. ET. The presentation will be
broadcast live over the Internet and archived for three months. Interested
parties may tune in to the live presentation by visiting the Company's
website at: www.cbiolabs.com or at www.two-007.net. It is recommended that
interested parties register at least 15 minutes prior to the start of the
presentation to ensure timely access.
Cleveland BioLabs currently has two lead compounds in late stages of
development. Curaxin CBLC102 is an orally administered small molecule
designed to kill tumor cells by simultaneously targeting two key regulators
of apoptosis. The Company has an ongoing Phase II trial with CBLC102 in
hormone refractory prostate cancer.
The Company's other lead compound, Protectan CBLB502, is a modified protein
of a microbe that temporarily protects cells from regulated cell death.
CBLB502 is the first compound of its kind to provide protection from both
gastrointestinal and hematopoietic (bone marrow/blood production)
radiation-induced damage. CBLB502 is being developed initially as a
radiation antidote for the military, rescue workers, nuclear plant
personnel and eventually for all people who may be subject or vulnerable to
nuclear attack or accident. Other applications for this technology include
protection from cancer treatment side effects and acute organ failure.
Earlier this year, the Company submitted CBLB502 to the Department of
Defense (DoD) in response to a Request for Proposal (RFP) for medical
radiation countermeasures to treat gastrointestinal effects of acute
radiation syndrome. The RFP award would provide funding for development of
the countermeasure through FDA approval, as well as a commitment to
purchase up to 500,000 doses, thereafter. The Company expects the DoD to
make its decision on the RFP later this year.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries about programmed cell death to treat
cancer and protect normal tissues from exposure to radiation and other
stresses. The Company has strategic partnerships with the Cleveland Clinic
Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the
Armed Forces Research Radiobiology Institute. To learn more about
Cleveland BioLabs Inc., please visit the company's website at
http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. Our actual
results could differ materially from those anticipated in these
forward-looking statements as a result of various factors. Some of the
factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in our filings with the Securities and Exchange
Commission.